Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Norovirus vaccine quadrivalent-Anhui Zhifei Longcom Biologic Pharmacy (Primary)
Indications Norovirus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Anhui Zhifei Longcom Biopharmaceutical

Most Recent Events

28 Aug 2024 Planned End Date changed from 30 Jun 2024 to 30 Dec 2024.
28 Aug 2024 Planned primary completion date changed from 2 Feb 2024 to 1 Nov 2024.
28 Feb 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight